New Two-Drug attack on tough ovarian cancer
NCT ID NCT06065462
Summary
This study is testing whether combining the immunotherapy drug dostarlimab with an experimental drug called LB-100 can help control a specific, hard-to-treat type of ovarian cancer that has come back. It is for adults aged 18-75 whose cancer has returned after at least one prior treatment and who do not have a specific genetic mutation (PPP2R1A). The main goals are to see if the treatment is safe and if it helps patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CLEAR CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.